PD-L1表达的核医学成像促进靶向放射性核素治疗与免疫检查点阻断的协同抗肿瘤疗效
研究开发了靶向整合素αvβ3的长效放射性治疗药物177Lu-AB-3PRGD2,在动物模型中开展靶向放射性核素治疗(TRT)与抗PD-L1免疫检查点阻断(ICB)的多种联合方案;用99mTc-MY1523 SPECT/CT显像评估TRT后肿瘤PD-L1表达变化,发现抗PD-L1治疗在PD-L1表达上调期间更有效,且该时间窗可由99mTc-MY1523 SPECT/CT确定。
要点
- 177Lu-AB-3PRGD2较前体提高肿瘤摄取并延长滞留,显著增强肿瘤生长抑制。
- 177Lu-AB-3PRGD2 TRT上调肿瘤PD-L1表达并增加瘤内CD8+ T细胞,重塑免疫微环境。
- 抗PD-L1治疗在PD-L1表达上调期间更有效,时间窗可由99mTc-MY1523 SPECT/CT确定。
核心结论
- 研究开发了新型长效放射性治疗药物177Lu-AB-3PRGD2,并开创了以PD-L1靶向核医学成像指导TRT与ICB联合的精准癌症治疗策略,以优化疗效并降低费用和潜在毒性风险。
- 作者认为该策略也可适应临床实践,将常规放疗或化疗与ICB联合以增强疗效。
研究设计与样本
- 在动物模型中开展177Lu-AB-3PRGD2 TRT以及177Lu-AB-3PRGD2 TRT与抗PD-L1 ICB的不同类型联合治疗。
- 在体外和体内用99mTc-MY1523的PD-L1特异性SPECT/CT显像评估TRT后肿瘤PD-L1表达变化。
主要发现
- 177Lu-AB-3PRGD2表现出改善的肿瘤摄取和延长的肿瘤滞留,导致显著增强的肿瘤生长抑制。
- 177Lu-AB-3PRGD2 TRT通过上调PD-L1表达和增加肿瘤浸润CD8+ T细胞重塑肿瘤免疫微环境,促进免疫治疗。
- 抗PD-L1治疗在肿瘤PD-L1表达上调期间更有效,该时间窗可由99mTc-MY1523 SPECT/CT确定。
临床怎么用
- 作者认为该策略可适应临床实践,将常规放疗或化疗与ICB联合以增强疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In order to maximize synergistic effect of targeted radionuclide therapy (TRT) and immune checkpoint blockade (ICB) as well as reduce the toxicity, we pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision cancer therapy. METHODS: As a novel targeted radiotherapeutic agent, 177Lu-AB-3PRGD2 targeting integrin αvβ3 was developed to achieve sustained antitumor effect by introducing an albumin binder (AB) into the structure of 3PRGD2. The 177Lu-AB-3PRGD2 TRT as well as different types of combination therapies of 177Lu-AB-3PRGD2 TRT and anti-PD-L1 ICB were performed in animal models. The changes of PD-L1 expression in tumors after TRT were evaluated in vitro and in vivo by PD-L1-specific SPECT/CT imaging of 99mTc-MY1523. RESULTS: 177Lu-AB-3PRGD2 showed improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. Moreover, 177Lu-AB-3PRGD2 TRT remodeled the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8+ T cells, facilitating immunotherapy. We found that the anti-PD-L1 treatment was more effective during the upregulation of tumor PD-L1 expression, and the time window could be determined by 99mTc-MY1523 SPECT/CT. CONCLUSION: We developed a novel and long-acting radiotherapeutic agent 177Lu-AB-3PRGD2, and pioneered a strategy guided by PD-L1-targeted nuclear medicine imaging for the combination of TRT and ICB towards precision cancer therapy, optimizing the therapeutic efficacy and reducing the cost and potential toxicity risks. This strategy could also be adapted for clinical practice, combining conventional radiotherapy or chemotherapy with ICB to enhance therapeutic efficacy.
引用
- Shi J, Gao H, Wu Y, et al. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2024. PMID: 39472367. doi:10.1007/s00259-024-06962-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。